Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease.
about
Diagnostic accuracy of pleural fluid NT-pro-BNP for pleural effusions of cardiac origin: a systematic review and meta-analysisSERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.Comparison of pleural fluid N-terminal pro-brain natriuretic peptide and brain natriuretic-32 peptide levels.Left ventricular diastolic function in relation to the urinary proteome: a proof-of-concept study in a general population.Left Ventricular Dysfunction and CXCR3 Ligands in Hypertension: From Animal Experiments to a Population-Based Pilot StudyDiagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure.Prevalence of left ventricular diastolic dysfunction in European populations based on cross-validated diagnostic thresholds.The effects of physical exercise on plasma levels of relaxin, NTproANP, and NTproBNP in patients with ischemic heart diseaseThe association between N-terminal pro B-type natriuretic peptide and lipoprotein particle concentration plateaus at higher N-terminal pro B-type natriuretic peptide values: Multi-Ethnic Study on AtherosclerosisChanges in N-terminal pro-B-type natriuretic peptide and incidence of diabetes: The Multi-Ethnic Study of Atherosclerosis (MESA)Dynamics of brain natriuretic peptide in critically ill patients with severe sepsis and septic shockSome heterogeneity factors affecting the B-type natriuretic peptides outcome: a meta-analysis.Novel Urinary Peptidomic Classifier Predicts Incident Heart Failure.Determinants of submaximal exercise capacity in patients at risk for heart failure with preserved ejection fraction-results from the DIAST-CHF study.Simple and sensitive detection of HBsAg by using a quantum dots nanobeads based dot-blot immunoassay.Effects of tilting and volume loading on plasma levels and urinary excretion of relaxin, NT-pro-ANP, and NT-pro-BNP in male volunteers.The effects of variations in thoracic blood volume and intravenous sodium loading on plasma levels of NTproANP and NTproBNP in healthy volunteers.Biochemical diagnosis of impaired left ventricular ejection fraction--comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP).Effects of thyroid hormone withdrawal on natriuretic peptides during radioactive iodine therapy in female patients with differentiated thyroid cancer.N-terminal brain natriuretic propeptide levels correlate with procalcitonin and C-reactive protein levels in septic patients.N-terminal prohormone brain natriuretic peptide-proBNP levels in ventricular arrhythmias in children.Clinical value of a competitive NT-proBNP enzyme immunoassay compared to the Roche NT-proBNP platform.Value of amino-terminal pro B-natriuretic peptide in diagnosing Kawasaki disease.Diagnostic accuracy of plasma brain natriuretic peptide and aminoterminal-proBNP in mild heart failure depends on assay and introduction of therapy.Cardiac troponin T and N-terminal-pro-B type natriuretic peptide reflect myocardial function in preterm infants
P2860
Q21257189-814E8FD2-03C1-45F6-87BD-B630C13FC8D7Q33589653-2C11F282-EF7C-4AB2-AD0A-5CC733E67CE4Q33897209-6675E9EB-3B5F-4677-9518-66296F36E2B7Q34140378-4B36EB6B-3C45-4D47-A3F1-C3413B75A86BQ34499585-8EE4BE26-8020-4EDF-8758-6B22DCD1DFCBQ35584077-5AAA0526-8142-43EC-85BB-A1E9E0B09150Q35955411-8703BBD5-B839-465A-8160-4BDA797AF89EQ35959425-BBC25BF2-1674-4F24-9E7E-0DCC8E84E66AQ36663488-BDC02CAA-6E1C-4024-BDEA-ABA97CF9BEE4Q36697650-7C1EF4F2-B050-459F-B068-9961DB4FF05FQ37133738-20E19154-F32A-4A3E-8D5F-F23505511273Q37313438-5C7085A7-3BFB-48F6-92CA-7F85354D1DFEQ40091740-CED36B1D-82DB-4791-B10C-20DF3A2587FFQ41706534-1F5A7169-5A87-47F0-BD19-9AC0B18C0015Q41918012-A27A4757-7D3F-4510-8320-C1CD392053C4Q44780506-D3C58CA3-779B-4D37-A4A3-26FD60DFE36EQ45836081-0ED71DE7-67BB-423A-B973-9B8C53744F60Q47829865-45D79309-3837-4678-8CA2-85CCCD09DC97Q47994657-5179D350-C105-48A7-A8D9-BE1F57A2D367Q48346519-FDCF446A-80D6-4A78-A53F-9926B87534BCQ48371711-47F4AB72-47AF-484E-836D-76900C63E19CQ48460261-26EA0A08-CD09-4547-BE03-A97861176CD8Q51403839-4B00173B-3667-4BD2-8635-6CE9D40D6FD5Q54330038-F5D120B0-1C75-4F82-B03B-CBAD782D381EQ57794316-5779A8DC-23FA-4F86-86C1-C63E46CDC185
P2860
Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Comparison of the Biomedica NT ...... atic structural heart disease.
@en
Comparison of the Biomedica NT ...... atic structural heart disease.
@nl
type
label
Comparison of the Biomedica NT ...... atic structural heart disease.
@en
Comparison of the Biomedica NT ...... atic structural heart disease.
@nl
prefLabel
Comparison of the Biomedica NT ...... atic structural heart disease.
@en
Comparison of the Biomedica NT ...... atic structural heart disease.
@nl
P2093
P356
P1433
P1476
Comparison of the Biomedica NT ...... atic structural heart disease.
@en
P2093
Alfons Gegenhuber
Meinhard Haltmayer
Thomas Mueller
Werner Poelz
P304
P356
10.1373/49.6.976
P407
P433
P577
2003-06-01T00:00:00Z